System and method for increasing the depth of focus of the human eye

Abstract
A method and apparatus for increasing the depth of focus of the human eye is comprised of a lens body, an optic in the lens body configured to produce light interference, and a pinhole-like optical aperture substantially in the center of the optic. The optic may be configured to produce light scattering or composed of a light reflective material. Alternatively, the optic may increase the depth of focus via a combination of light interference, light scattering, light reflection and/or light absorption. The optic may also be configured as a series of concentric circles, a weave, a pattern of particles, or a pattern of curvatures. One method involves screening a patient for an ophthalmic lens using a pinhole screening device in the lens to increase the patient's depth of focus. Another method comprises surgically implanting a mask in the patient's eye to increase the depth of focus.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


The invention generally relates to ophthalmic lenses and, more particularly, the invention relates to ophthalmic lenses for increasing the depth of focus of the human eye.


2. Description of the Related Art


It is well-known that the depth of focus of the human eye can be increased with the use of ophthalmic lenses with pinhole-like apertures substantially near the optical center of the lens. For example, U.S. Pat. No. 4,976,732 (“the '732 patent”) discloses an ophthalmic lens with a pinhole-like aperture. In the '732 patent, a mask forms the pinhole-like aperture. In one embodiment, the mask is circular in shape. When the pupil is constricted, light enters the retina through the pinhole-like aperture. When the pupil is dilated, light enters the retina through the pinhole-like aperture and the outer edges of the mask.


In addition, U.S. Pat. No. 3,794,414 (“the '414 patent”) discloses a contact lens with a pinhole-like aperture. In the '414 patent, the mask forming the pinhole-like aperture has radial slits and/or scalloped edges. In addition, the mask forming the pinhole-like aperture is two spaced-apart concentric circles. However, the radial slits, scalloped edges and two spaced-apart concentric circles promote light diffraction, which in turn reduces the contrast of the image.


In U.S. Pat. Nos. 4,955,904, 5,245,367, 5,757,458 and 5,786,883, various modifications to an ophthalmic lens with a pinhole-like aperture are disclosed. For example, the patents disclose use of an optical power for vision correction in the pinhole-like aperture, or use of an optical power for vision correction in the area outside the mask. In contrast, in U.S. Pat. No. 5,980,040, the mask is powered. In particular, the mask is powered to bend the light passing through the mask to impinge on the retina at a radial distance outside of the fovea. In other words, the mask is powered to “defocus” the light.


In each of these patents, the mask forming the pinhole-like aperture is made, in whole or in part, of a light absorptive material. A light-absorptive material is a material in which light is lost as it passes through the material, generally due to conversion of the light into another form of energy, e.g., heat.


SUMMARY OF THE INVENTION

In accordance with an embodiment of the invention, an ophthalmic lens comprises a lens body, an optic located in the lens body, the optic configured to produce light interference, and a pinhole-like optical aperture substantially in the center of the optic. In a further embodiment of the invention, the optic is configured to positively interfere with parallel light reaching the optic and negatively interfere with diverging light reaching the optic. In addition, some diverging light may pass through the optic. In this alternate embodiment of the invention, the optic is configured to spread out the diverging light passing through the optic.


In an alternate embodiment of the invention, an ophthalmic lens comprises a lens body, an optic located in the lens body, the optic configured to produce light scattering, and a pinhole-like optical aperture substantially in the center of the optic. In a further embodiment of the invention, the optic is configured to forward scatter parallel light reaching the optic and back scatter diverging light reaching the optic.


In another alternative embodiment of the invention, an ophthalmic lens comprises a lens body, an optic located in the lens body, the optic configured to produce light reflection, and a pinhole-like optical aperture substantially in the center of the optic. In an alternate embodiment of the invention, the optic is composed, in whole or in part, of a light reflective material.


In further embodiments of the inventions, the optic may be configured as a series of concentric circles, a weave, a pattern of particles, or a pattern of curvatures. In addition, the pinhole-like aperture includes an optical power for vision correction, and may have a diameter in the range of substantially 0.05 mm to substantially 5.0 mm. Further, the optic may have an outer diameter in the range of substantially 1.0 mm to substantially 8.0 mm. The optic may also be composed of a material having varying degrees of opacity, and the ophthalmic lens and the optic may be composed of a bio-compatible, non-dissolving material, such as polymethyl methacrylate or a medical polymer.


In accordance with another embodiment of the invention, a method for screening a patient for an ophthalmic lens, the ophthalmic lens having a pinhole-like optical aperture, comprises fitting each of the patient's eyes with a first contact lens, placing a mask on each of the first contact lens, the mask configured to produce a pinhole-like aperture in each of the first contact lens, fitting each of the patient's eyes with a second contact lens, the second contact lens being placed over the mask to hold the mask in a substantially constant position, and testing the patient's vision.


In further embodiments of the invention, the mask may be a light interference mask, a light scattering mask, or a light reflective mask. The first contact lens may include an optical power for vision correction. In addition, each of the first and second contact lenses may be soft contact lenses. Further, the mask for each of the patient's eyes may have a light absorption of substantially 100%. In the alternative, the mask for each of the patient's eyes may be composed of a polarized material.


In still further embodiments of the invention, the process of testing comprises testing the patient's acuity for distance vision under bright and dim lighting conditions, testing the patient's acuity for near vision under bright and dim lighting conditions, and testing the patient's contrast sensitivity under bright and dim lighting conditions. The process of testing may further comprise testing a patient's visual acuity using a night driving simulation. The night driving simulation may include a series of objects and road signs under bright and dim lighting conditions, as well as having the patient face a simulated oncoming automobile headlight.


In an alternate embodiment of the invention, the process of testing comprises replacing the mask in one of the patient's eyes with a mask having a light L absorption of substantially 85% or less, then, if needed, replacing the mask in the patient's other eye with a mask having a light absorption of substantially 85% or less. Further, the process of testing comprises, if needed, removing the mask from one of the patient's eyes.


In another alternate embodiment of the invention, the process of testing comprises placing an analyzer in the spectacle plane of one of the patient's eyes, the analyzer including a polarizing element, rotating the polarizing element to achieve an optimal balance of contrast and brightness, and determining the resultant light absorption of the mask. In addition, the process of testing may include evaluating the cosmetic appearance of the mask.


In accordance with a still another embodiment of the invention, a method for implanting a mask in a cornea, the mask configured to increase the depth of focus of the human eye, comprises removing the epithelial sheet, creating a depression in the Bowman's membrane, the depression being of sufficient depth and width to expose the top layer of the stroma and accommodate the mask, placing the mask in the depression, and placing the removed epithelial sheet over the mask. In a further embodiment of the invention, the depression may extend into the top layer of the stroma.


In an alternate embodiment of the invention, a method for implanting a mask in a cornea, the mask configured to increase the depth of focus of the human eye, comprises hinging open a portion of the Bowman's membrane, creating a depression in the top layer of the stroma, the depression being of sufficient depth and width to accommodate the mask, placing the mask in the depression, and placing the hinged Bowman's membrane over the mask.


In another alternate embodiment of the invention, a method for implanting a mask in a cornea, the mask configured to increase the depth of focus of the human eye, comprises creating a channel in the top layer of the stroma, the channel being in a plane parallel to the cornea's surface, and placing the mask in the channel. In this embodiment, the mask may be threaded into the channel, or the mask may be injected into the channel.


In still another alternate embodiment of the invention, a method for implanting a mask in a cornea, the mask configured to increase the depth of focus of the human eye, comprises penetrating the top layer of the stroma with an injecting device, and injecting the mask into the top layer of the stroma with the injecting device. In this embodiment, the injecting device may be a ring of needles. In addition, the mask may be a pigment, or the mask may be composed of pieces of pigmented material suspended in a bio-compatible medium. The pigmented material may be made of a medical polymer, e.g., suture material.


In one other alternate embodiment of the invention, a method for implanting a mask in a cornea, the mask configured to increase the depth of focus of the human eye, comprises hinging open a corneal flap, the corneal flap comprising substantially the outermost 20% of the cornea, placing the mask on the cornea, and placing the hinged corneal flap over the mask.


In still one other alternate embodiment of the invention, a method for implanting a mask in a cornea, the mask configured to increase the depth of focus of the human eye, comprises creating a pocket in the stroma, the pocket being of sufficient size to accommodate the mask, and-placing the mask in the created pocket.


In further embodiments of the inventions, the mask may be a light interference optic, a light scattering optic, or a light reflective optic. In addition, the mask may block visual aberrations. In addition, after surgery, a contact lens may be placed over at least the affected portion of the cornea.





BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other objects and advantages of the invention will be appreciated more fully from the following further description thereof with reference to the accompanying drawings wherein:



FIGS. 1
a and 1b show an exemplary ophthalmic lens with an exemplary optic configured to produce light interference.



FIGS. 2
a and 2b show another exemplary ophthalmic lens with another exemplary optic configured to produce light interference.



FIGS. 3
a and 3b show an exemplary ophthalmic lens with an exemplary optic configured to produce light scattering.



FIGS. 4
a and 4b show an exemplary ophthalmic lens with an exemplary optic configured to produce light reflection.



FIG. 5 shows an exemplary process for screening a patient interested in an ophthalmic lens with a pinhole-like aperture using an exemplary pinhole screening device.



FIGS. 6
a through 6c show a mask, configured to increase the depth of focus of the human eye, inserted underneath the cornea's epithelium sheet.



FIGS. 7
a through 7c show a mask, configured to increase the depth of focus of the human eye, inserted beneath the cornea's Bowman's membrane.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

In accordance with an embodiment of the invention, an ophthalmic lens (e.g., a contact lens, an intra ocular lens, a corneal inlay lens, etc.) increases the depth of focus of the human eye through the use of an optic. The optic surrounds a pinhole-like optical aperture near the optical center of the lens. The pinhole-like aperture in conjunction with the optic increases the depth of focus of the human eye. In particular, the optic increases the depth of focus of the human eye using light interference, light scattering, light reflection, light absorption and/or a combination of one or more of these properties. An optic configured in accordance with the various embodiments of the invention is referred to as a Paraxial Adaptive Optic™.



FIGS. 1
a and 1b show an exemplary ophthalmic lens with an exemplary optic configured to produce light interference. FIG. 1a shows a front view of the exemplary ophthalmic lens. FIG. 1b shows a side view of the exemplary optic implanted in the cornea of a human eye.


Light interference is the additive process in which the amplitude of two or more overlapping light waves is either attenuated or reinforced. For example, when two overlapping light waves are in-phase (the crest and trough of one wave coincides with the crest and trough of the other wave), then the amplitude of the resultant light wave is reinforced. This type of interference is referred to as positive interference. In contrast, when two overlapping light waves are out-of-phase (the crest of one wave coincides with the trough of the other wave), then the amplitude of the resultant light wave is attenuated. This type of interference is referred to as negative interference. Of course, light interference also occurs between the two extremes of in-phase and out-of-phase.


As shown in FIGS. 1a and 1b, optic 100 is located substantially in the center of lens body 110. Optic 100 surrounds optical aperture 120 located near the optical center of lens body 110. The specific location of optical aperture 120 in lens body 110 varies in accordance with the patient's eye. Specifically, optical aperture 120 is positioned in lens body 10 to be concentric with the patient's pupil.


In operation, optical aperture 120 increases the depth of focus of the human eye via a “pinhole effect.” In particular, optical aperture 120 increases depth of focus by limiting the light reaching the retina to plane wavefront light. In photonics, a wavefront is a surface connecting all points equidistant from a source. Plane wavefront light is relatively parallel light, e.g., light from a distant source. It is “relatively” parallel light because, in reality, even light from a distant star is diverging light. In contrast, convex wavefront light is relatively diverging light, e.g., light from a near source. It is easier for the human eye to focus plane wavefront light because the crystalline lens of the human eye can focus parallel light on the retina with little or no accommodation. In accommodation, the crystalline lens, through the action of the ciliary muscles, thickens and, thereby, changes its degree of curvature.


In order to achieve a useful “pinhole effect,” optical aperture 120 should have a diameter in the range of substantially 0.05 millimeters (“mm”) to substantially 5.0 mm. In addition, in order to aid examination of the retina and increase brightness when the pupil is dilated, the outer diameter of optic 100 should be in the range of substantially 1.0 mm to substantially 8.0 mm. Moreover, to further improve vision, optical aperture 120 may include an optical power for vision correction, e.g., correction for near vision, correction for distance vision, correction for intermediate vision, etc. Also, the area outside optic 100 may include an optical power for vision correction.


In operation, optic 100 increases the depth of focus of the human eye via its configuration. In particular, optic 100 is configured to produce light interference via a series of concentric circles. Specifically, optic 100 is configured to reinforce relatively parallel light and attenuate relatively diverging light. When optic 100 attenuates less than all of the relatively diverging light, then optic 100 is further configured to spread out the diverging light that passes through optic 100, i.e., weakening the diverging light passing through optic 100. Thus, because diverging light is attenuated and/or weakened, the “pinhole effect” of optical aperture 120 is increased for relatively near objects, producing a higher contrast depth of focus image of relatively near objects. Moreover, because parallel light is reinforced, the “pinhole effect” of optical aperture 120 is reduced, producing a brighter image of relatively distant objects.


Optic 100 is also configured to effect the chromatic aberration of the human eye. The human eye's chromatic aberration, in which the size of an image appears to change when the color of the image is changed, results from the normal increase in refractive index toward the blue end of the color spectrum. In optic 100, the increase in refractive index is toward the red end of the color spectrum. Thus, optic 100 may reduce or cancel the chromatic aberration of the human eye.


Further, optic 100 is configured to meet the specific needs of the patient. For example, a person of skill in the art understands that, among other things, the addition of concentric circles, the removal of concentric circles, the change in spacing between concentric circles, the varying of spacing between concentric circles, and the shape of the concentric circles (e.g., oval, round, elliptical, etc.) would influence the light interference properties of optic 100.



FIGS. 2
a and 2b show another exemplary ophthalmic lens with another exemplary optic configured to produce light interference. In this exemplary embodiment, optic 200 is configured to produce light interference via a weave. As discussed in regard to optic 100, the weave reinforces relatively parallel light and attenuates relatively diverging light. Depending on the weave's material, the weave may also absorb light coming into contact with the weave's material. FIG. 2a shows a front view of the exemplary ophthalmic lens. FIG. 2b shows a side view of the exemplary optic implanted in the cornea of a human eye.


As discussed in regard to optic 100, optic 200 is configured to meet the specific needs of the patient. For example, a person of skill in the art understands that, among other things, the density of the weave would influence the light interference properties of optic 200.



FIGS. 3
a and 3b show an exemplary ophthalmic lens with an exemplary optic configured to produce light scattering. FIG. 3a shows a front view of the exemplary ophthalmic lens. FIG. 3b shows a side view of the exemplary optic implanted in the cornea of a human eye.


In general, light scattering is the deflection of light upon interaction with a medium. Light is forward scattered when, upon interaction with a medium, it is deflected through angles of 90°. or less with respect to the original direction of motion. Light is back scattered when, upon interaction with a medium, it is deflected through angles in excess of 90°. with respect to the original direction of motion.


As shown in FIGS. 3a and 3b, optic 300 is located substantially in the center of lens body 310. Optic 300 surrounds optical aperture 320 located near the optical center of lens body 310. The specific location of optical aperture 320 in lens body 310 varies in accordance with the patient's eye. Specifically, optical aperture 320 is positioned in lens body 310 to be concentric with the patient's pupil.


As discussed in regard to optical apertures 120 and 220, optical aperture 320 increases the depth of focus of the human eye via a “pinhole effect.” Similarly, as discussed in regard to optics 100 and 200, optic 300 increases the depth of focus of the human eye via its configuration. In particular, optic 300 is configured to produce light scattering via a pattern of particles. Specifically, optic 300 is configured to forward scatter relatively parallel light and back scatter relatively diverging light. Thus, because diverging light is back scattered, the “pinhole effect” of optical aperture 320 is increased for relatively near objects, producing a higher contrast depth of focus image of relatively near objects. Moreover, because parallel light is forward scattered, the “pinhole effect” of optical aperture 320 is reduced, producing a brighter image of relatively distant objects.


Further, optic 300 is configured to meet the specific needs of the patient. For example, a person of skill in the art understands that, among other things, the light absorption of the particles, the index of refraction of the particles, the index of refraction of the media surrounding the particles, the size of the particles, and the space between the particles would influence the light scattering properties of optic 300. In addition, optic 300 may be configured to produce light interference, as discussed in regard to optics 100 and 200.



FIGS. 4
a and 4b show an exemplary ophthalmic lens with an exemplary optic configured to produce light reflection. FIG. 4a shows a front view of the exemplary ophthalmic lens. FIG. 4b shows a side view of the exemplary optic implanted in the cornea of a human eye.


Optic 400 is located substantially in the center of lens body 410. Optic 400 surrounds optical aperture 420 located near the optical center of lens body 410. The specific location of optical aperture 420 in lens body 410 varies in accordance with the patient's eye. Specifically, optical aperture 420 is positioned in lens body 410 to be concentric with the patient's pupil.


As discussed in regard to optical apertures 120, 220 and 320, optical aperture 420 increases the depth of focus of the human eye via a “pinhole effect.” Similarly, as discussed in regard to optics 100, 200 and 300, optic 400 increases the depth of focus of the human eye via its configuration. In particular, optic 400 is configured to reflect light, in whole or in part, via a pattern of curvatures. Specifically, optic 400 is configured to favor transmission of the light to which the retinal rods are more sensitive, i.e., dim light and/or blue light, and to block the light to which retinal cones are more sensitive, i.e., bright light. Thus, because bright light is blocked, the “pinhole effect” of optical aperture 420 is increased for relatively near objects, producing a higher contrast depth of focus image of relatively near objects. Moreover, because dim light and/or blue light is transmitted, the “pinhole effect” of optical aperture 420 is reduced, producing a brighter image of relatively distant objects.


In an alternate embodiment, optic 400 may be composed, in whole or in part, of a light reflective material. A light reflective material is a material that, in whole or in part, reflects back light coming into contact with the material.


Further, optic 400 may be configured to meet the specific needs of the patient. For example, a person of skill in the art understands that, among other things, the type of material, the thickness of material, and the curvature of material would influence the light reflective properties of optic 400. In addition, optic 400 may be configured to produce light interference and/or light scattering, as discussed in regard to optics 100, 200 and 300, respectively.


In a particular embodiment of the ophthalmic lens described in FIG. 4, optic 400 is composed of a light reflective material with a peak transmission of substantially 550 nanometers (“nm”). A light-adapted retina has a peak transmission at 550 nm. In contrast, a dark-adapted retina has a peak transmission at 500 nm. Thus, an optic with a peak transmission of substantially 550 nm filters out more light with a peak transmission of 500 nm, i.e., bright light, than light with a peak transmission of 550 nm, i.e., dim light. Thus, as discussed above, because bright light is blocked, the “pinhole effect” of optical aperture 420 is increased for relatively near objects, producing a higher contrast depth of focus image of relatively near objects. Moreover, because dim light is transmitted, the “pinhole effect” of optical aperture 420 is reduced, producing a brighter image of relatively distant objects.


Further, this particular embodiment of optic 400 may be configured to meet the specific needs of the patient. For example, a person of skill in the art understands that, among other things, the peak transmission of the mask may be changed, e.g., to a peak transmission of 500 nm. In addition, the mask may be composed of material, other than light reflective material, which also allows the desired peak transmissions.


In alternate embodiments, the optic is composed of bio-compatible, non-dissolving material, e.g., polymethyl methacrylate or medical polymers. In addition, the optic may be composed, in whole or in part, of a light reflective material or, in whole or in part, of a light absorptive material. Further, the optic may be composed, in whole or in part, of a material having varying degrees of opacity. The optic may also be configured to produce light interference, light-scattering and light reflection, or some combination of one or more of these properties. Moreover, the optic may be colored to match the color of a patient's iris.


In accordance with a further embodiment of the invention, a patient interested in an ophthalmic lens with a pinhole-like aperture is screened using soft contact lenses and a mask, referred to as a pinhole screening device. The mask may be an optic as described in the prior art, an optic as described herein, or an optic combining one or more of these properties. After insertion of the pinhole screening device, the patient's vision is tested.



FIG. 5 shows an exemplary process for screening a patient interested in an ophthalmic lens with a pinhole-like aperture using an exemplary pinhole screening device. The process begins at step 500, in which the patient is fitted with soft contact lenses, i.e., a soft contact lens in placed in each of the patient's eyes. If needed, the soft contact lenses may include vision correction. Next, at step 510, a mask is placed on the soft contact lenses. The mask should be placed concentric with the patient's pupil. In addition, the curvature of the mask should parallel the curvature of the patient's cornea. The process continues at step 520, in which the patient is fitted with a second set of soft contact lenses, i.e., a second soft contact lens is placed over the mask in each of the patient's eyes. The second contact lens holds the mask in a substantially constant position. Last, at step 530, the patient's vision is tested. During testing, it is advisable to check the positioning of the mask to ensure it remains concentric with the patient's pupil.


A test of the patient's vision may include testing the patient's acuity for distance vision under bright and dim lighting conditions, testing the patient's acuity for near vision under bright and dim lighting conditions, and testing the patient's contrast sensitivity under bright and dim lighting conditions. In addition, the test may include testing the patient's visual acuity using a night driving simulation. A night driving simulation may include a series of objects and road signs under bright and dim lighting conditions, as well as a simulated oncoming automobile headlight.


The test of the patient's vision may further include changing the mask. For example, the test might first be conducted using, in each of the patient's eyes, a mask having a light absorption of substantially 100%. If, for example, the patient experiences a sense of dimness, the mask in one of the patient's eyes may be replaced with a mask having a light absorption of substantially 85%. If, for example, the sense of dimness continues, the mask in the patient's other eye may be replaced with a mask having a light absorption of substantially 85%. Then, for example, if the sense of dimness continues, the mask may be removed from one of the patient's eyes.


In the alternate, the mask in one of the patient's eyes may be replaced with a mask having a light absorption less than substantially 85%. If, for example, the patient experiences a sense of dimness with a mask having a light absorption of substantially 100%, then the mask in one of the patient's eyes may be replaced with a mask having a light absorption of substantially 75%. If, for example, the sense of dimness continues, the mask in the patient's other eye may be replaced with a mask having a light absorption of substantially 75%. Then, for example, if the sense of dimness continues, the 75% mask may be replaced with a mask having a light absorption of substantially 50%.


As can be seen, there are numerous permutations for thoroughly screening the patient to find the optimal balance of contrast and brightness. In effect, the, mask in each of the patient's eyes is replaced, every other time, with a mask having a different light absorption than the replaced mask. This process continues until the optimal balance of contrast and brightness is found.


The process for changing the mask while testing the patient's vision also includes changing from an optic as described in the prior art to an optic as described herein. In addition, various mask configurations may be used. For example, an optic having both light interference and light scattering may be used, or an optic having both light reflective and light absorptive properties may be used. Once again, the numerous permutations allow for thoroughly screening the patient to find the optimal balance of contrast and brightness prior to, for example, the doctor placing a customized order or the patient undergoing invasive surgery.


The test of the patient's vision may also include evaluating the cosmetic appearance of the mask. For example, if the patient is dissatisfied with the appearance of the mask, the mask can be replaced with a mask of appropriate configuration colored to match the patient's iris.


In an alternate testing process, the mask placed on the soft contact lens in each of the patient's eyes is composed of a polarized material. A polarized material has a light absorption of substantially 50%. Then, an analyzer, which contains a polarized element, is used to help calculate the patient's optimal light absorption properties for the mask. In the process, the analyzer is placed in the spectacle plane of one of the patient's eyes and the polarized element in the analyzer is rotated until the patient experiences an optimal balance of contrast and brightness. The process may be repeated for the patient's other eye.


Using the analyzer, the doctor may now calculate the resultant light absorption of the mask. If desired, a mask of similar light absorption, whether it be an optic as described in the prior art, an optic as described herein, or an optic combining one or more of these properties, can now be placed between the contact lenses in each of the patient's eyes and the patient's vision tested, as described above.


In accordance with a still further embodiment of the invention, a mask is surgically implanted into the eye of a patient interested in increasing his or her depth of focus. For example, the patient may suffer from presbyopia, a condition in which the crystalline lens can no longer accommodate near vision because of a loss of elasticity in the lens or a weakness in the ciliary muscle. The mask may be an optic as described in the prior art, an optic as described herein, or an optic combining one or more of these properties. Further, the mask may be configured to correct visual aberrations. To aid the surgeon surgically implanting a mask into a patient's eye, the mask may be pre-rolled or folded for ease of implantation.


The mask may be implanted in several locations. For example, the mask may be implanted underneath the cornea's epithelium sheet, beneath the cornea's Bowman membrane, in the top layer of the cornea's stroma, or in the cornea's stroma. When the mask is placed underneath the cornea's epithelium sheet, removal of the mask requires little more than removal of the cornea's epithelium sheet.



FIGS. 6
a through 6c show mask 600 inserted underneath epithelium sheet 610. In this embodiment, the surgeon first removes epithelium sheet 610. For example, as shown in FIG. 6a, epithelium sheet 610 may be rolled back. Then, as shown in FIG. 6b, the surgeon creates depression 615 in Bowman's member 620. Depression 615 should be of sufficient depth and width to both expose top layer 630 of stroma 640 and to accommodate mask 600. Mask 600 is then placed in depression 615. Last, epithelium sheet 610 is placed over mask 600. Over time, as shown in FIG. 6c, epithelium sheet 610 will grow and adhere to top layer 630 of stroma 640, as well as mask 600 depending, of course, on the composition of mask 600. As needed, a contact lens may be placed over the incised cornea to protect the mask.



FIGS. 7
a through 7c show mask 700 inserted beneath Bowman's membrane 720. In this embodiment, as shown in FIG. 7a, the surgeon first hinges open Bowman's member 720. Then, as shown in FIG. 7b, the surgeon creates depression 715 in top layer 730 of stroma 740. Depression 715 should be of sufficient depth and width to accommodate mask 700. Then, mask 700 is placed in depression 715. Last, Bowman's member 720 is placed over mask 700. Over time, as shown in FIG. 7c, epithelium sheet 710 will grow over the incised area of Bowman's member 720. As needed, a contact lens may be placed over the incised cornea to protect the mask.


In an alternate embodiment, a mask of sufficient thinness, i.e., less than substantially 20 microns, may be placed underneath epithelium sheet 610, or beneath Bowman's member 720, without creating a depression in the top layer of the stroma.


In an alternate method for surgically implanting a mask in the eye of a patient, the mask may be threaded into a channel created in the top layer of the stroma. In this method, a curved channeling tool creates a channel in the top layer of the stroma, the channel being in a plane parallel to the surface of the cornea. The channeling tool either pierces the surface of the cornea or, in the alternative, is inserted via a small superficial radial incision. In the alternative, a laser focusing an ablative beam may create the channel in the top layer of the stroma. In this embodiment, the mask may be a single segment with a break, or it may be two or more segments.


In another alternate method for surgically implanting a mask in the eye of a patient, the mask may be injected into the top layer of the stroma. In this embodiment, an injection tool with a stop penetrates the surface of the cornea to the specified depth. For example, the injection tool may be a ring of needles capable of producing a mask with a single injection. In the alternative, a channel may first be created in the top layer of the stroma. Then, the injector tool may inject the mask into the tunnel. In this embodiment, the mask may be a pigment, or it may be pieces of pigmented material suspended in a bio-compatible medium. The pigment material may be made of a polymer or, in the alternative, made of a suture material.


In still another alternate method for surgically implanting a mask in the eye of a patient, the mask may be placed beneath the corneal flap created during keratectomy, when the outermost 20% of the cornea is hinged open.


In one still other alternate method for surgically implanting a mask in the eye of a patient, the mask may be placed in a pocket created in the cornea's stroma.


Although various exemplary embodiments of the invention have been disclosed, it should be apparent to those skilled in the art that various changes and modifications can be made which will achieve some of the advantages of the invention without departing from the true scope of the invention. These and other obvious modifications are intended to be covered by the appended claims.

Claims
  • 1. A method for implanting a mask in a cornea comprising an epithelial sheet, a Bowman's membrane, and a stroma, the stroma having a top layer, the method comprising: creating a flap in a portion of the cornea;creating a depression in the top layer of the stroma by completely removing a portion of the stroma from the cornea, the depression being of sufficient depth and width to accommodate a mask, the mask comprising a centrally located pinhole-like optical aperture and a structure surrounding the aperture, the structure further having varying degrees of opacity, each of the varying degrees of opacity preventing transmission of a substantial portion of visible light incident on the structure;placing the mask in the depression; andplacing the flap over the mask,wherein the mask increases the depth of focus of the eye and a curvature of the cornea is not substantially changed after placing the mask.
  • 2. The method of claim 1, wherein the mask is configured to produce light interference.
  • 3. The method of claim 1, wherein the mask is configured to produce light scattering.
  • 4. The method of claim 1, wherein the mask is configured to produce reflection.
  • 5. The method of claim 1, wherein the mask is configured to block visual aberrations.
  • 6. The method of claim 1, further comprising: placing a contact lens over at least a portion of the cornea until the epithelial sheet has grown over the hinged Bowman's membrane.
  • 7. A method for implanting an ophthalmic device in a cornea comprising an epithelial sheet, a Bowman's membrane, and a stroma, the stroma having a top layer, the method comprising: creating a channel in the stroma by completely removing a portion of the stroma from the cornea, the channel being in a plane parallel to the cornea's surface; andplacing an ophthalmic device in the channel, the ophthalmic device comprising a mask comprising a centrally located pinhole-like optical aperture and a structure surrounding the aperture, the structure further having varying degrees of opacity, each of the varying degrees of opacity preventing transmission of a substantial portion of visible light incident on the structure,wherein the mask increases the depth of focus of the eye and a curvature of the cornea is not substantially changed after implanting the mask.
  • 8. The method of claim 7, wherein the mask is configured to produce light interference.
  • 9. The method of claim 7, wherein the mask is configured to produce light scattering.
  • 10. The method of claim 7, wherein the mask is configured to produce light reflection.
  • 11. The method of claim 7, wherein the mask is configured to block visual aberrations.
  • 12. The method of claim 7, further comprising threading the mask into the channel.
  • 13. The method of claim 7, further comprising injecting the mask into the channel.
  • 14. A method for implanting a mask in a cornea, the mask configured to increase the depth of focus of the human eye, the cornea comprising an epithelium sheet, the method comprising: forming a corneal flap, the corneal flap comprising substantially the outermost 20% of the cornea;placing a mask on a portion of the cornea exposed by the flap, the mask configured to provide an optical effect whereby the depth of focus of the human eye is increased, the mask comprising a centrally located pinhole-like optical aperture and a structure surrounding the aperture, the structure further having varying degrees of opacity, each of the varying degrees of opacity preventing transmission of a substantial portion of visible light incident on the structure; andplacing the corneal flap over the mask,wherein a curvature of the cornea is not substantially changed after implanting the mask.
  • 15. The method of claim 14, wherein the mask is configured to produce light interference.
  • 16. The method of claim 14, wherein the mask is configured to produce light scattering.
  • 17. The method of claim 14, wherein the mask is configured to produce light reflection.
  • 18. The method of claim 14, wherein the mask is configured to block visual aberrations.
  • 19. The method of claim 14, further comprising: placing a contact lens over a portion of the cornea until the epithelial sheet has grown over the hinged corneal flap.
  • 20. A method for implanting an ophthalmic device in a cornea comprising a stroma, the method comprising: creating a pocket in the stroma, the pocket being of sufficient size to accommodate an ophthalmic device, the ophthalmic device comprising a mask configured to provide an optical effect whereby the depth of focus of the human eye is increased, the mask comprising a centrally located pinhole-like optical aperture and a structure surrounding the aperture, the structure further having varying degrees of opacity, each of the varying degrees of opacity preventing transmission of a substantial portion of visible light incident on the structure; andplacing the ophthalmic device in the pocket,wherein a curvature of the cornea is not substantially changed after implanting the mask.
  • 21. The method of claim 20, wherein the mask is configured to produce light interference.
  • 22. The method of claim 20, wherein the mask is configured to produce light scattering.
  • 23. The method of claim 20, wherein the mask is configured to produce light reflection.
  • 24. The method of claim 20, wherein the mask is configured to block visual aberrations.
RELATED APPLICATIONS

This application is a divisional application of U.S. patent application Ser. No. 11/284,791, filed Nov. 22, 2005, now U.S. Pat. No. 7,404,638, which is a divisional application of U.S. patent application Ser. No. 10/729,200, filed Dec. 5, 2003, now U.S. Pat. No. 6,966,648, which is a divisional of U.S. patent application Ser. No. 10/384,957, filed Mar. 10, 2003, now U.S. Pat. No. 6,874,886, which is a divisional of U.S. patent application Ser. No. 09/516,258, filed Feb. 29, 2000, now U.S. Pat. No. 6,554,424, which claimed priority from provisional U.S. Patent Application Ser. No. 60/122,001, filed Mar. 1, 1999, entitled “SCREENING TECHNIQUES AND DEVICES USED PRIOR TO THE INSERTION OF A CORNEAL ANNULUS INLAY;” provisional U.S. Patent Application Ser. No. 60/124,345, filed Mar. 15, 1999, entitled “NEW METHOD OF INCREASING THE DEPTH OF FOCUS OF THE HUMAN EYE;” and provisional U.S. Patent Application Ser. No. 60/138,110, filed Jun. 7, 1999, entitled “WOVEN ANNULAR MASK CORNEAL INLAY.” This application is also a divisional application of U.S. patent application Ser. No. 09/516,258, filed Feb. 29, 2000, now U.S. Pat. No. 6,554,424. The disclosures of all these applications are incorporated herein, in their entirety, by reference.

US Referenced Citations (440)
Number Name Date Kind
564518 Heilborn Jul 1896 A
1206132 Otte Nov 1916 A
1959915 Guthrie May 1934 A
2129305 Feinbloom Sep 1938 A
2714721 Stone, Jr. Aug 1955 A
3034403 Neefe Apr 1959 A
3270099 Camp Aug 1966 A
3339997 Wesley Sep 1967 A
3458870 Stone, Jr. Aug 1969 A
3507566 Knapp Apr 1970 A
3578850 Grant May 1971 A
3600098 Mohrman Aug 1971 A
3726587 Kendall Apr 1973 A
3794414 Wesley Feb 1974 A
3852032 Urbach Dec 1974 A
3982541 L'Esperance, Jr. Sep 1976 A
4010496 Neefe Mar 1977 A
4073015 Peyman Feb 1978 A
4099529 Peyman Jul 1978 A
4138191 Peyman Feb 1979 A
4191195 Miller Mar 1980 A
4272191 Bergkvist Jun 1981 A
4298004 Schachar et al. Nov 1981 A
4312575 Peyman et al. Jan 1982 A
4367949 Lavering Jan 1983 A
4402681 Haas et al. Sep 1983 A
4450593 Poler May 1984 A
4452235 Reynolds Jun 1984 A
4485499 Castleman Dec 1984 A
4528311 Beard et al. Jul 1985 A
4536240 Winn Aug 1985 A
4547914 Castleman Oct 1985 A
4547915 Castleman Oct 1985 A
4575915 Clark et al. Mar 1986 A
4576453 Borowsky Mar 1986 A
4607617 Choyce Aug 1986 A
4612012 White Sep 1986 A
4615702 Koziol et al. Oct 1986 A
4617023 Peyman Oct 1986 A
4624669 Grendahl Nov 1986 A
4633866 Peyman et al. Jan 1987 A
4636049 Blaker Jan 1987 A
4636211 Nielsen et al. Jan 1987 A
4636212 Posin et al. Jan 1987 A
4637697 Freeman Jan 1987 A
4639105 Neefe Jan 1987 A
4641934 Freeman Feb 1987 A
4642112 Freeman Feb 1987 A
4646720 Peyman et al. Mar 1987 A
4655774 Choyce Apr 1987 A
4662370 Hoffman et al. May 1987 A
4665913 L'Esperance, Jr. May 1987 A
4666446 Koziol et al. May 1987 A
4669466 L'Esperance, Jr. Jun 1987 A
4669834 Richter Jun 1987 A
4674503 Peyman et al. Jun 1987 A
4676790 Kern Jun 1987 A
4676791 LeMaster et al. Jun 1987 A
4685922 Peyman Aug 1987 A
4701038 Neefe Oct 1987 A
4702865 Koziol et al. Oct 1987 A
4704016 de Carle Nov 1987 A
4710003 Masuda et al. Dec 1987 A
4713446 DeVore et al. Dec 1987 A
4715858 Lindstrom Dec 1987 A
4718418 L'Esperance Jan 1988 A
4729372 L'Esperance, Jr. Mar 1988 A
4729373 Peyman Mar 1988 A
4744360 Bath May 1988 A
4753654 Posin et al. Jun 1988 A
4779973 Miller et al. Oct 1988 A
4785796 Mattson Nov 1988 A
4799784 Safir Jan 1989 A
4799931 Lindstrom Jan 1989 A
4807623 Lieberman Feb 1989 A
4808181 Kelman Feb 1989 A
4813955 Achatz et al. Mar 1989 A
4814050 McGraw et al. Mar 1989 A
4838266 Koziol et al. Jun 1989 A
4840175 Peyman Jun 1989 A
4842599 Bronstein Jun 1989 A
4851003 Lindstrom Jul 1989 A
4863466 Schlegel Sep 1989 A
4865601 Caldwell et al. Sep 1989 A
4869587 Breger Sep 1989 A
4878910 Koziol et al. Nov 1989 A
4881954 Bikson et al. Nov 1989 A
4890913 De Carle Jan 1990 A
4891043 Zeimer et al. Jan 1990 A
4898461 Portney Feb 1990 A
4903695 Warner et al. Feb 1990 A
4923297 Arndt May 1990 A
4932970 Portney Jun 1990 A
4955904 Atebara et al. Sep 1990 A
4958922 Binh et al. Sep 1990 A
4961744 Kilmer et al. Oct 1990 A
4965545 Johnson Oct 1990 A
4971432 Koeniger Nov 1990 A
4976732 Vorosmarthy Dec 1990 A
4983181 Civerchia Jan 1991 A
4985559 Goldberg et al. Jan 1991 A
4990165 Bikson et al. Feb 1991 A
4994058 Raven et al. Feb 1991 A
4994080 Shepard Feb 1991 A
4997268 Dauvergne Mar 1991 A
5002571 O'Donnell, Jr. Mar 1991 A
5013319 Davis May 1991 A
5019097 Knight et al. May 1991 A
5026393 Mackool Jun 1991 A
5030230 White Jul 1991 A
5041133 Sayano et al. Aug 1991 A
5061914 Busch et al. Oct 1991 A
5063942 Kilmer et al. Nov 1991 A
5067961 Kelman et al. Nov 1991 A
5076684 Simpson et al. Dec 1991 A
5089022 Koester et al. Feb 1992 A
5089024 Christie et al. Feb 1992 A
5098443 Parel et al. Mar 1992 A
5098444 Feaster Mar 1992 A
5104957 Kelman et al. Apr 1992 A
5108169 Mandell Apr 1992 A
5108428 Capecchi et al. Apr 1992 A
5112350 Civerchia et al. May 1992 A
5116111 Simpson et al. May 1992 A
5119555 Johnson Jun 1992 A
5120120 Cohen Jun 1992 A
5123921 Werblin et al. Jun 1992 A
5133745 Falcetta et al. Jul 1992 A
5149331 Ferdman et al. Sep 1992 A
5152789 Willis Oct 1992 A
5160463 Evans et al. Nov 1992 A
5165897 Johnson Nov 1992 A
5166712 Portney Nov 1992 A
5171318 Gibson et al. Dec 1992 A
5185152 Peyman Feb 1993 A
5192316 Ting Mar 1993 A
5192318 Schneider et al. Mar 1993 A
5196026 Barrett et al. Mar 1993 A
5215104 Steinert Jun 1993 A
5219844 Peyman et al. Jun 1993 A
5225858 Portney Jul 1993 A
5239066 Falkow et al. Aug 1993 A
5245367 Miller et al. Sep 1993 A
5245738 Johnson Sep 1993 A
5258412 Peyman et al. Nov 1993 A
5260727 Oksman et al. Nov 1993 A
5261997 Inselmann Nov 1993 A
5269812 White Dec 1993 A
5270744 Portney Dec 1993 A
5274404 Michael Dec 1993 A
5292514 Capecchi et al. Mar 1994 A
5296881 Freeman Mar 1994 A
5300116 Chirila et al. Apr 1994 A
5300118 Silvestrini et al. Apr 1994 A
5302978 Evans et al. Apr 1994 A
5310654 Isberg et al. May 1994 A
5312393 Mastel May 1994 A
5314439 Sugita May 1994 A
5314961 Anton et al. May 1994 A
5315344 Clark et al. May 1994 A
5318044 Kilmer et al. Jun 1994 A
5318047 Davenport et al. Jun 1994 A
5323788 Silvestrini et al. Jun 1994 A
5325880 Johnson et al. Jul 1994 A
5336261 Barret et al. Aug 1994 A
5346689 Peyman et al. Sep 1994 A
5354331 Schachar Oct 1994 A
5366499 Py Nov 1994 A
5368604 Kilmer et al. Nov 1994 A
5374272 Arpa et al. Dec 1994 A
D354566 Donahoo Jan 1995 S
5391201 Barret et al. Feb 1995 A
5401508 Manesis Mar 1995 A
5403335 Loomas et al. Apr 1995 A
5405384 Silvestrini Apr 1995 A
5422424 Selsted et al. Jun 1995 A
5433745 Graham et al. Jul 1995 A
5434630 Bransome Jul 1995 A
5437274 Khoobehi et al. Aug 1995 A
5458819 Chirila et al. Oct 1995 A
5474548 Knopp et al. Dec 1995 A
5476515 Kelman et al. Dec 1995 A
5480427 Kelman et al. Jan 1996 A
5489300 Capecchi et al. Feb 1996 A
5496339 Koepnick Mar 1996 A
5505723 Muller Apr 1996 A
5507740 O'Donnel, Jr. Apr 1996 A
5516522 Peyman et al. May 1996 A
5522888 Civerchia Jun 1996 A
5526178 Goldstein et al. Jun 1996 A
5527356 Peyman et al. Jun 1996 A
5547473 Peyman Aug 1996 A
5567365 Weinschenk, III et al. Oct 1996 A
5571177 Deacon et al. Nov 1996 A
5579063 Magnante et al. Nov 1996 A
RE35421 Ruiz et al. Jan 1997 E
5599537 Miller, III et al. Feb 1997 A
5605938 Roufa et al. Feb 1997 A
5608471 Miller Mar 1997 A
5610719 Allen et al. Mar 1997 A
5628794 Lindstrom May 1997 A
5628795 Langerman May 1997 A
5628798 Eggleston et al. May 1997 A
5631243 Kelman et al. May 1997 A
5632773 Graham et al. May 1997 A
5662706 Legerton et al. Sep 1997 A
5662908 Falkow et al. Sep 1997 A
5672885 Allen et al. Sep 1997 A
5674724 Miller, III et al. Oct 1997 A
5674736 Miller, III et al. Oct 1997 A
5693092 Silvestrini et al. Dec 1997 A
5695983 Miller et al. Dec 1997 A
5697923 Poler Dec 1997 A
5697973 Peyman et al. Dec 1997 A
5702440 Portney Dec 1997 A
5713844 Peyman Feb 1998 A
5713957 Steele et al. Feb 1998 A
5719656 Bowling Feb 1998 A
5720894 Neev et al. Feb 1998 A
5722971 Peyman Mar 1998 A
5731196 Miller, III et al. Mar 1998 A
5731862 Winkler Mar 1998 A
5733760 Lu et al. Mar 1998 A
5752967 Kritzinger et al. May 1998 A
5757458 Miller et al. May 1998 A
5771088 Perrott Jun 1998 A
5771742 Bokaie et al. Jun 1998 A
5774202 Abraham et al. Jun 1998 A
5782911 Herrick Jul 1998 A
5786883 Miller et al. Jul 1998 A
5800533 Eggleston et al. Sep 1998 A
5806530 Herrick Sep 1998 A
5814680 Imafuku et al. Sep 1998 A
5836313 Perez et al. Nov 1998 A
5840848 Sturrock et al. Nov 1998 A
5855605 Herrick Jan 1999 A
5858980 Weiner et al. Jan 1999 A
5861486 Devore et al. Jan 1999 A
5863537 Dalie et al. Jan 1999 A
5864128 Plesko Jan 1999 A
5864378 Portney Jan 1999 A
5874537 Kelman et al. Feb 1999 A
5903099 Johnson et al. May 1999 A
5905561 Lee et al. May 1999 A
5919185 Peyman Jul 1999 A
5929968 Cotie et al. Jul 1999 A
5946748 Wang Sep 1999 A
5960812 Johnson Oct 1999 A
5964748 Peyman Oct 1999 A
5964776 Peyman Oct 1999 A
5965330 Evans et al. Oct 1999 A
5980040 Xu et al. Nov 1999 A
5997559 Ziemer Dec 1999 A
6010901 Miller, III et al. Jan 2000 A
6024447 Portney Feb 2000 A
6036957 Weiner et al. Mar 2000 A
6050999 Paraschac et al. Apr 2000 A
6063073 Peyman May 2000 A
6083236 Feingold Jul 2000 A
6086204 Magnante Jul 2000 A
6090141 Lindstrom Jul 2000 A
6096077 Callahan et al. Aug 2000 A
6102946 Nigam Aug 2000 A
6106552 Lacombe et al. Aug 2000 A
6126286 Portney Oct 2000 A
6161544 DeVore et al. Dec 2000 A
6164282 Gwon et al. Dec 2000 A
6165189 Ziemer Dec 2000 A
6171336 Sawusch Jan 2001 B1
6176878 Gwon et al. Jan 2001 B1
6183498 Devore et al. Feb 2001 B1
6197019 Peyman Mar 2001 B1
6197057 Peyman et al. Mar 2001 B1
6197934 DeVore et al. Mar 2001 B1
6203538 Peyman Mar 2001 B1
6204365 Devore et al. Mar 2001 B1
6210005 Portney Apr 2001 B1
6217571 Peyman Apr 2001 B1
6217596 Farah Apr 2001 B1
6221067 Peyman Apr 2001 B1
6221105 Portney Apr 2001 B1
6228114 Lee May 2001 B1
6251118 Proudfoot et al. Jun 2001 B1
6277146 Peyman et al. Aug 2001 B1
6280470 Peyman Aug 2001 B1
6280471 Peyman Aug 2001 B1
6283595 Breger Sep 2001 B1
6335006 Miller Jan 2002 B1
6357875 Herrick Mar 2002 B1
6358280 Herrick Mar 2002 B1
6361560 Nigam Mar 2002 B1
6387379 Goldberg et al. May 2002 B1
6391055 Ikada et al. May 2002 B1
6403947 Hoyt et al. Jun 2002 B1
6406494 Laguette et al. Jun 2002 B1
6416179 Lieberman et al. Jul 2002 B1
6423093 Hicks et al. Jul 2002 B1
6436092 Peyman Aug 2002 B1
6457826 Lett Oct 2002 B1
6458141 Peyman Oct 2002 B1
6470108 Johnson Oct 2002 B1
6488707 Callahan et al. Dec 2002 B1
6494910 Ganem et al. Dec 2002 B1
6497700 LaHaye Dec 2002 B1
6503276 Lang et al. Jan 2003 B2
6527389 Portney Mar 2003 B2
6533905 Johnson et al. Mar 2003 B2
6536899 Fiala Mar 2003 B1
6551307 Peyman Apr 2003 B2
6554424 Miller et al. Apr 2003 B1
6555103 Leukel et al. Apr 2003 B2
6569199 Dotan et al. May 2003 B1
6581993 Nigam Jun 2003 B2
RE38193 Bowling Jul 2003 E
6588022 Anders et al. Jul 2003 B1
6588902 Isogai Jul 2003 B2
6589280 Koziol Jul 2003 B1
6592621 Domino Jul 2003 B1
6599305 Feingold Jul 2003 B1
6607556 Nigam Aug 2003 B1
6613088 Babizhayev Sep 2003 B1
6614570 Johnson et al. Sep 2003 B2
6620634 Johnson et al. Sep 2003 B2
6623497 Feingold Sep 2003 B1
6623522 Nigam Sep 2003 B2
6624730 Johnson et al. Sep 2003 B2
6626941 Nigam Sep 2003 B2
6632244 Nigam Oct 2003 B1
6663668 Chaouk et al. Dec 2003 B1
6669795 Johnson et al. Dec 2003 B2
6673112 Nigam Jan 2004 B2
6729599 Johnson May 2004 B2
6740116 Morcher May 2004 B2
6742761 Johnson et al. Jun 2004 B2
6746890 Gupta et al. Jun 2004 B2
6755858 White Jun 2004 B1
6786926 Peyman Sep 2004 B2
6790298 Johnson et al. Sep 2004 B2
6811256 Becherer et al. Nov 2004 B1
6849090 Nigam Feb 2005 B2
6855163 Peyman Feb 2005 B2
6874886 Miller et al. Apr 2005 B2
6899424 Miller et al. May 2005 B2
6949093 Peyman Sep 2005 B1
6951556 Epstein Oct 2005 B2
6966648 Miller et al. Nov 2005 B2
6976997 Noolandi et al. Dec 2005 B2
7025455 Roffman Apr 2006 B2
7207998 Feingold Apr 2007 B2
7364674 Hoover Apr 2008 B1
7404637 Miller et al. Jul 2008 B2
7404638 Miller et al. Jul 2008 B2
7491350 Silvestrini Feb 2009 B2
7628810 Christie et al. Dec 2009 B2
7645291 Ross et al. Jan 2010 B2
7828844 Marmo et al. Nov 2010 B2
20010004702 Peyman Jun 2001 A1
20010027314 Peyman Oct 2001 A1
20010034516 Peyman Oct 2001 A1
20010047203 Dalton et al. Nov 2001 A1
20010050750 Breger Dec 2001 A1
20020010510 Silvestrini Jan 2002 A1
20020028330 Patel et al. Mar 2002 A1
20020055753 Silvestrini May 2002 A1
20020057148 Johnson et al. May 2002 A1
20020075447 Andino et al. Jun 2002 A1
20020107337 Rosenzweig et al. Aug 2002 A1
20020107566 Nigam Aug 2002 A1
20020111677 Nigam Aug 2002 A1
20020128710 Eggleston Sep 2002 A1
20020167640 Francis et al. Nov 2002 A1
20020188351 Laguette Dec 2002 A1
20020196409 Jani Dec 2002 A1
20030002994 Johnson et al. Jan 2003 A1
20030007122 Streibig Jan 2003 A1
20030014042 Juhasz et al. Jan 2003 A1
20030014107 Reynard Jan 2003 A1
20030033013 Callahan et al. Feb 2003 A1
20030045930 Nguyen Mar 2003 A1
20030055497 Hicks et al. Mar 2003 A1
20030071893 Miller et al. Apr 2003 A1
20030078655 Callahan et al. Apr 2003 A1
20030088313 Nigam May 2003 A1
20030093083 Peyman May 2003 A1
20030105521 Perez Jun 2003 A1
20030127318 Johnson et al. Jul 2003 A1
20030220653 Perez Nov 2003 A1
20040014253 Gupta et al. Jan 2004 A1
20040015234 Peyman Jan 2004 A1
20040019379 Glick et al. Jan 2004 A1
20040047014 Parker et al. Mar 2004 A1
20040068317 Knight Apr 2004 A1
20040078075 Koziol Apr 2004 A1
20040080239 Gupta et al. Apr 2004 A1
20050027355 Murakami Feb 2005 A1
20050031697 Vehige et al. Feb 2005 A1
20050033420 Christie et al. Feb 2005 A1
20050046794 Silvestrini et al. Mar 2005 A1
20050049621 Feingold et al. Mar 2005 A1
20050080485 Nigam Apr 2005 A1
20050119738 Nigam Jun 2005 A1
20050124983 Frey et al. Jun 2005 A1
20050143812 Paul et al. Jun 2005 A1
20050182488 Peyman Aug 2005 A1
20050187621 Brady Aug 2005 A1
20050228376 Boomer et al. Oct 2005 A1
20060079959 Christie et al. Apr 2006 A1
20060079960 Christie et al. Apr 2006 A1
20060113054 Silvestrini Jun 2006 A1
20060184243 Yilmaz Aug 2006 A1
20060235514 Silvestrini Oct 2006 A1
20060241751 Marmo et al. Oct 2006 A1
20060265058 Silvestrini Nov 2006 A1
20060268226 Christie et al. Nov 2006 A1
20060268227 Christie et al. Nov 2006 A1
20060268228 Christie et al. Nov 2006 A1
20060268229 Silvestrini et al. Nov 2006 A1
20060270946 Silvestrini et al. Nov 2006 A1
20060271026 Silvestrini et al. Nov 2006 A1
20060271027 Silvestrini et al. Nov 2006 A1
20060271176 Christie et al. Nov 2006 A1
20060271177 Christie et al. Nov 2006 A1
20060271178 Christie et al. Nov 2006 A1
20060271179 Christie et al. Nov 2006 A1
20060271180 Christie et al. Nov 2006 A1
20060271181 Christie et al. Nov 2006 A1
20060271182 Christie et al. Nov 2006 A1
20060271183 Christie et al. Nov 2006 A1
20060271184 Silvestrini Nov 2006 A1
20060271185 Silvestrini Nov 2006 A1
20060274264 Christie et al. Dec 2006 A1
20060274265 Christie et al. Dec 2006 A1
20070016234 Daxer Jan 2007 A1
20070219542 Yahagi Sep 2007 A1
20070225691 Silvestrini et al. Sep 2007 A1
20080151183 Altmann Jun 2008 A1
20090059168 Miller et al. Mar 2009 A1
20090069817 Peyman Mar 2009 A1
20090222086 Lui et al. Sep 2009 A1
20110040376 Christie et al. Feb 2011 A1
Foreign Referenced Citations (32)
Number Date Country
0 457 553 Nov 1991 EP
369 993 Jan 1907 FR
2599156 May 1986 FR
2649605 Jan 1991 FR
1 026 839 Apr 1966 GB
1276003 Jun 1972 GB
62167343 Jul 1987 JP
03-001857 Jan 1991 JP
04-158859 Jun 1992 JP
07-178125 Jul 1995 JP
07-265340 Oct 1995 JP
2138837 Sep 1999 RU
1380743 Mar 1998 SU
WO 9405232 Mar 1994 WO
WO 9423327 Oct 1994 WO
WO 9502356 Jan 1995 WO
WO 9503747 Feb 1995 WO
WO 9508135 Mar 1995 WO
WO 9635397 Nov 1996 WO
WO 9748004 Dec 1997 WO
WO 9748005 Dec 1997 WO
WO 9907309 Feb 1999 WO
WO 0052516 Sep 2000 WO
WO 0052516 Sep 2000 WO
WO 0119364 Mar 2001 WO
WO 0227388 Apr 2002 WO
WO 02102241 Dec 2002 WO
WO 03030763 Apr 2003 WO
WO 2004050132 Jun 2004 WO
WO 2004105588 Dec 2004 WO
WO 2006047698 May 2006 WO
WO 2008036671 Mar 2008 WO
Related Publications (1)
Number Date Country
20090021692 A1 Jan 2009 US
Provisional Applications (3)
Number Date Country
60122001 Mar 1999 US
60124345 Mar 1999 US
60138110 Jun 1999 US
Divisions (6)
Number Date Country
Parent 11284791 Nov 2005 US
Child 12182056 US
Parent 10729200 Dec 2003 US
Child 11284791 US
Parent 10384957 Mar 2003 US
Child 10729200 US
Parent 09516258 Feb 2000 US
Child 10384957 US
Parent 12182056 US
Child 10384957 US
Parent 09516258 Feb 2000 US
Child 12182056 US